Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13931070 | 0.85 | CCR5 (0.36) | LMNAALDH1A1SMN1; SMN2NPY2RKMT2A | |
| SCHEMBL13930709 | 0.81 | MAPT (0.42) | LMNAALDH1A1GAASMN1; SMN2NPY2R | |
| SCHEMBL13931006 | 0.80 | RAB9A (0.46) | ALDH1A1NPY2RRAB9AFUCA1CCR5 | |
| SCHEMBL13952282 | 0.78 | RAB9A (0.45) | ALDH1A1NPY2RRAB9AFUCA1CCR5 | |
| SCHEMBL4254638 | 0.76 | RAB9A (0.47) | SMN1; SMN2RAB9ATSHRTP53FUCA1 | |
| SCHEMBL4254635 | 0.76 | RAB9A (0.47) | SMN1; SMN2RAB9ATSHRTP53FUCA1 | |
| SCHEMBL13931035 | 0.74 | CCR5 (0.40) | LMNAALDH1A1GAASMN1; SMN2NPY2R | |
| SCHEMBL13931036 | 0.74 | CCR5 (0.40) | LMNAALDH1A1GAASMN1; SMN2NPY2R | |
| SCHEMBL13930701 | 0.72 | CCR5 (0.55) | CCR5 | |
| SCHEMBL13930705 | 0.72 | CCR5 (0.55) | CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | ALDH1A1, ABAT, ALDH18A1 | LMNA 3911/4885ALDH1A1 1/4885GAA 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.